Plain-English translation of NCT07271342 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →This study is collecting real-world information about how well works when doctors use it to treat stroke patients in regular hospitals across China. Unlike controlled research studies in controlled settings, this registry captures what actually happens when patients with different health conditions and stroke types receive this medication in everyday practice.
The medication was recently approved for stroke treatment in China, but doctors need to understand how it performs in real hospitals with real patients who have various health conditions and complications—information that controlled trials don't always capture.
You likely qualify if…
You likely don't qualify if…
You would be enrolled after receiving the medication for your stroke at the hospital. Your doctors will collect information about your treatment, how you respond to the medication, and any side effects you experience. You'll complete follow-up assessments to track your recovery—these may include visits, tests, or phone check-ins, depending on the hospital and your condition.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Enrollment target
~10,000 participants
Started
November 2025
Primary completion
March 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongjun Wang, MD
Beijing Tiantan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.